You are here

  • Home
  • Archive
  • Volume 9, Issue 9
  • Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

 

Online download statistics by month:

Online download statistics by month: September 2021 to September 2024

AbstractFullPdf
Sep 2021507507160
Oct 202124824990
Nov 202114214264
Dec 202110010024
Jan 202211111955
Feb 2022687136
Mar 2022697144
Apr 2022858737
May 2022989933
Jun 2022839546
Jul 2022596221
Aug 2022707232
Sep 2022819361
Oct 2022687330
Nov 2022606033
Dec 2022353616
Jan 2023424444
Feb 2023818234
Mar 2023282915
Apr 2023293121
May 2023222215
Jun 2023404020
Jul 2023383931
Aug 2023424217
Sep 2023414129
Oct 2023262623
Nov 2023404016
Dec 2023494921
Jan 2024424323
Feb 2024575820
Mar 20246162157
Apr 2024363626
May 202410510621
Jun 2024555444
Jul 2024596134
Aug 2024615923
Sep 2024444427
Total288229441443